DOCSLIB.ORG

IG Living October-November 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IG Living October-November 2017 October-Novembervember 2017 IGLiving.com Managing Changesges in Senior Care Traansitioning IG Coverage too Medicare Understanding MannoseMannose-Binding Binding Mediccal Intervention IG Paatient Care Lectin Deficiencyy for DeDepressionepression in Nursingng Homes On IGLiving.com Feaatures an easy- to-nnavigate design Indepth content onn IG-treated diseases annd treatment Cononnnnectnne withh oouurur Pattiiieeent Advocateee,, AAbbbbie Cornett RReeaead weeklyklylyy bblogs about isssues relal tted d to living with cchchrhroononionic illnessnessessessss Valuablee Resourcees and more On Facebook Findd timely and relevant informao tion posted dailyy, providing a venue foro connnecting with others in the IG community. On the Go contents October-November 2017 5 Editorial The Challenges of Aging with PI By Ronale Tucker Rhodes, MS 18 Moving Aging IG Patients into 6 Abbie’s Corner Nursing Homes IDF Says Goodbye to a Legendary Leader By Abbie Cornett and By Abbie Cornett Roger H. Kobayashi, MD 7 Faces of IG From our Facebook page 22 Transitioning IG Coverage By Abbie Cornett to Medicare By Michelle Greer, RN, and Leslie Vaughan, RPh 26 Chronic Illness and Depression By Trudie Mitschang 8 Ask the Experts Healthcare professionals’ 33 Understanding Mannose- responses to patient questions Binding Lectin Deficiency By Dana Henry 9 Immunology 101 DiGeorge Syndrome: Further Discussion of Neurologic/ Behavioral Issues By Terry O. Harville, MD, PhD 42 Product Guide 10 Clinical Brief Itching for Relief Immune Globulin Differentiation By Trudie Mitschang By Elissa Ritt, DHSc 44 Book Corner 12 In the News New and useful reading Research, science, product 46 Resource Center and insurance updates Community foundations, associations, forums and other resources Advertising in IG Living IG Living Magazine is read by 30,000 subscribers who are patients that depend upon immune globulin products and 36 Let’s Talk!—Chelsey Safken their healthcare providers. For information about advertising in IG Living, download a media kit at igliving.com/ By Trudie Mitschang Advertise.aspx. Or contact [email protected]. About IG Living 38 Patient Perspective — Smile and IG Living magazine brings together patients, advocates and caregivers in the immune globulin (IG) community. the World Will Smile with You IG Living, (ISSN 1949-4548), published bimonthly, is a community service provided by FFF Enterprises, 44000 Winchester Road, By Stacy Oliver Temecula, CA 92590, (800) 843-7477 x1362, fax (951) 699-9655. Subscriptions to IG Living are free, and readers may subscribe at IGLiving.com or by calling (800) 843-7477 x1351. 39 Life as a 20-Something — The opinions expressed in IG Living are those of the authors alone and do not represent the opinions, policies or positions of FFF Enterprises, the Board of Directors, the IG Living Advisory Board or editorial staff. This material is provided for general infor- An Accessible Apartment mation only. FFF Enterprises does not give medical advice or engage in the practice of medicine. FFF Enterprises under no cir- cumstances recommends any particular treatment for any individual and in all cases recommends that individuals consult with By Ilana Jacqueline a physician before pursuing any course of treatment. All manuscripts should be submitted in MS Word, in Arial font. Manuscripts should be between 650 and 1,300 words in 40 Parenting — Helping length, with unjustified margins and without any other formatting. Submission guidelines are available for download from the Children Understand Contact Us page on IGLiving.com. Email manuscripts to [email protected]. IG Living retains the right to edit submissions. The contents of each submission and their accuracy are the responsibility of the author(s) and must be original work that has Long-Term Illness not been, nor will be, published elsewhere, without the written permission of IG Living. A copyright agreement attesting to this and transferring copyright to FFF Enterprises will be required. Acceptance of advertising for products and services in IG By Jessica Leigh Johnson Living in no way constitutes endorsement by FFF Enterprises. ©2017 FFF Enterprises Inc. 4 IG Living | October-November 2017 | IGLiving.com UP FRONT Our mission is to support the IG community through education, The Challenges communication and advocacy of Aging with PI A community service from FFF Enterprises, Inc. SINCE THE FIRST discovery of a primary immunodeficiency (PI) disease (agamma- Advisory Board globulinemia) in 1952, the number of individuals diagnosed with PIs continues to Bob Geng, MD, MA expand rapidly. Today, there are more than 200 different forms of PI affecting approxi- Assistant Professor, Division of Allergy & Immunology 1 mately 500,000 people in the U.S.And, as the prevalence of PI grows, so does the number University of California, San Diego of discoveries about them, including the molecular causes. Currently, scientists have identified Erika Lawrence, PhD 320 molecularly defined PIs, with 22 genes known to be the cause. And, it is anticipated Associate Professor that as genetic research continues, some 500-plus genes will be identified. 2 Department of Psychology What does all this mean? First and foremost, as the causes of PIs are discovered,there will University of Iowa be more targeted therapies developed to keep PI patients alive for far longer than previously Todd Levine, MD Director, Department of Neurophysiology possible. And, while this is extremely good news, it also brings with it some challenges. One Good Samaritan Hospital, Phoenix that many immunologists are dealing with more frequently is how to transition senior PI Assistant Professor of Clinical Neurology patients into nursing homes equipped to deal with the special care they require. On the ground University of Arizona floor of this issue is immunologist Roger H. Kobayashi, who has co-authored withIG Living’s Fred Modell patient advocate, Abbie Cornett, the article “Moving Aging IG Patients into Nursing Homes.” Co-founder of the As they explain, because nursing homes cater to seniors, they are equipped to deal with the Jeffrey Modell Foundation common chronic conditions this population typically faces. But, PI differs by far from most of Marc Riedl, MD, MS those illnesses. Not only do susceptible PI patients have to be gravely concerned about infectious Associate Professor of Medicine diseases frequently circulating in nursing homes, but they have the added worry about how their Division of Rheumatology, Allergy & Immunology University of California, San Diego immune globulin (IG) treatment may be affected — particularly if they are treated at home. Dr. Kobayashi’s and Abbie’s advice concerning some very specific items to consider when choosing Publisher Patrick M. Schmidt a nursing home offers help to this growing PI demographic. Editor Ronale Tucker Rhodes, MS An equally challenging issue for aging patients treated with IG is insurance. At age 65, Assistant Editor Cheryl Brooks Art Director Allan Bean patients must enroll in Medicare, even if they have employer-sponsored insurance coverage. As our article “Transitioning IG Coverage to Medicare” explains, this transition “can be more complex than IG therapy!” As an update of an article topic that is covered every two years in Contributing Writers IG Living, it reflects a substantial number of changes to Medicare reimbursement. Individuals Abbie Cornett must be very careful to choose the Medicare plan that will provide the best reimbursement, Michelle Greer, RN Terry O. Harville, MD, PhD which will depend primarily on their diagnosis (PI or another), since coverage differs for each. Dana Henry In addition, we report on legislative issues that have complicated the reimbursement process Ilana Jacqueline for at-home treatment. Jessica Leigh Johnson The challenges PI patients face day in and day out are hard enough, without the added Roger H. Kobayashi, MD Trudie Mitschang burden of mental stress that can lead to depression. Indeed, as our article “Chronic Illness and Stacy Oliver Depression” highlights, approximately “one-third of individuals with a serious medical Leslie Vaughan, RPh condition experience symptoms of depression.” Considering this, it is hoped that patients will benefit from this article that explains the warning signs of depression, as well as outlines various treatment options. As always, I hope you gain insight from the information presented and enjoy this edition of IG Living. Ronale Tucker Rhodes, MS ©2017 FFF Enterprises Inc. All rights reserved. Please direct editorial, advertising and marketing communications to 1. National Institute of Allergy and Infectious Diseases. Primary Immune Deficiency Diseases (PIDDs). Accessed at www.niaid.nih.gov/diseases- 44000 Winchester Road conditions/primary-immune-deficiency-diseases-pidds. Temecula, CA 92590 2. Advances in Primary Immunodeficiency: Is It All in the Genes? 2017 Immune Deficiency Foundation National Conference Breakfast Symposium. Phone: (800) 843-7477 Email: [email protected] IGLiving.com ABBIE’S CORNER IDF Says Goodbye to a Legendary Leader By Abbie Cornett I’VE ALWAYS ENJOYED attending materials for patients and their families. national per-visit low-utilization payment the biannual Immune Deficiency Today, these materials are the leading amount under the prospective payment Foundation (IDF) conference. It is always sources of information for patients and system for home health services. held at an exciting location, and it pro- families worldwide. But, Marcia didn’t • Newborn screening for
Load more

Recommended publications
  • The Case for Lupus Nephritis
    Journal of Clinical Medicine Review Expanding the Role of Complement Therapies: The Case for Lupus Nephritis Nicholas L. Li * , Daniel J. Birmingham and Brad H. Rovin Department of Internal Medicine, Division of Nephrology, The Ohio State University, Columbus, OH 43210, USA; [email protected] (D.J.B.); [email protected] (B.H.R.) * Correspondence: [email protected]; Tel.: +1-614-293-4997; Fax: +1-614-293-3073 Abstract: The complement system is an innate immune surveillance network that provides defense against microorganisms and clearance of immune complexes and cellular debris and bridges innate and adaptive immunity. In the context of autoimmune disease, activation and dysregulation of complement can lead to uncontrolled inflammation and organ damage, especially to the kidney. Systemic lupus erythematosus (SLE) is characterized by loss of tolerance, autoantibody production, and immune complex deposition in tissues including the kidney, with inflammatory consequences. Effective clearance of immune complexes and cellular waste by early complement components protects against the development of lupus nephritis, while uncontrolled activation of complement, especially the alternative pathway, promotes kidney damage in SLE. Therefore, complement plays a dual role in the pathogenesis of lupus nephritis. Improved understanding of the contribution of the various complement pathways to the development of kidney disease in SLE has created an opportunity to target the complement system with novel therapies to improve outcomes in lupus nephritis. In this review, we explore the interactions between complement and the kidney in SLE and their implications for the treatment of lupus nephritis. Keywords: lupus nephritis; complement; systemic lupus erythematosus; glomerulonephritis Citation: Li, N.L.; Birmingham, D.J.; Rovin, B.H.
    [Show full text]
  • Are Complement Deficiencies Really Rare?
    G Model MIMM-4432; No. of Pages 8 ARTICLE IN PRESS Molecular Immunology xxx (2014) xxx–xxx Contents lists available at ScienceDirect Molecular Immunology j ournal homepage: www.elsevier.com/locate/molimm Review Are complement deficiencies really rare? Overview on prevalence, ଝ clinical importance and modern diagnostic approach a,∗ b Anete Sevciovic Grumach , Michael Kirschfink a Faculty of Medicine ABC, Santo Andre, SP, Brazil b Institute of Immunology, University of Heidelberg, Heidelberg, Germany a r a t b i c s t l e i n f o r a c t Article history: Complement deficiencies comprise between 1 and 10% of all primary immunodeficiencies (PIDs) accord- Received 29 May 2014 ing to national and supranational registries. They are still considered rare and even of less clinical Received in revised form 18 June 2014 importance. This not only reflects (as in all PIDs) a great lack of awareness among clinicians and gen- Accepted 23 June 2014 eral practitioners but is also due to the fact that only few centers worldwide provide a comprehensive Available online xxx laboratory complement analysis. To enable early identification, our aim is to present warning signs for complement deficiencies and recommendations for diagnostic approach. The genetic deficiency of any Keywords: early component of the classical pathway (C1q, C1r/s, C2, C4) is often associated with autoimmune dis- Complement deficiencies eases whereas individuals, deficient of properdin or of the terminal pathway components (C5 to C9), are Warning signs Prevalence highly susceptible to meningococcal disease. Deficiency of C1 Inhibitor (hereditary angioedema, HAE) Meningitis results in episodic angioedema, which in a considerable number of patients with identical symptoms Infections also occurs in factor XII mutations.
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]
  • European Society for Immunodeficiencies (ESID)
    Journal of Clinical Immunology https://doi.org/10.1007/s10875-020-00754-1 ORIGINAL ARTICLE European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline: Deficiencies, Diagnosis, and Management Nicholas Brodszki1 & Ashley Frazer-Abel2 & Anete S. Grumach3 & Michael Kirschfink4 & Jiri Litzman5 & Elena Perez6 & Mikko R. J. Seppänen7 & Kathleen E. Sullivan8 & Stephen Jolles9 Received: 5 June 2019 /Accepted: 20 January 2020 # The Author(s) 2020 Abstract This guideline aims to describe the complement system and the functions of the constituent pathways, with particular focus on primary immunodeficiencies (PIDs) and their diagnosis and management. The complement system is a crucial part of the innate immune system, with multiple membrane-bound and soluble components. There are three distinct enzymatic cascade pathways within the complement system, the classical, alternative and lectin pathways, which converge with the cleavage of central C3. Complement deficiencies account for ~5% of PIDs. The clinical consequences of inherited defects in the complement system are protean and include increased susceptibility to infection, autoimmune diseases (e.g., systemic lupus erythematosus), age-related macular degeneration, renal disorders (e.g., atypical hemolytic uremic syndrome) and angioedema. Modern complement analysis allows an in-depth insight into the functional and molecular basis of nearly all complement deficiencies. However, therapeutic options remain relatively limited for the majority of complement deficiencies with the exception of hereditary angioedema and inhibition of an overactivated complement system in regulation defects. Current management strategies for complement disor- ders associated with infection include education, family testing, vaccinations, antibiotics and emergency planning. Keywords Complement .
    [Show full text]
  • ESID Registry – Working Definitions for Clinical Diagnosis of PID
    ESID Registry – Working Definitions for Clinical Diagnosis of PID These criteria are only for patients with no genetic diagnosis*. *Exceptions: Atypical SCID, DiGeorge syndrome – a known genetic defect and confirmation of criteria is mandatory. Available entries (Please click on an entry to see the criteria.) Page Acquired angioedema .................................................................................................................................................................. 4 Agammaglobulinemia .................................................................................................................................................................. 4 Asplenia syndrome (Ivemark syndrome) ................................................................................................................................... 4 Ataxia telangiectasia (ATM) ......................................................................................................................................................... 4 Atypical Severe Combined Immunodeficiency (Atypical SCID) ............................................................................................... 5 Autoimmune lymphoproliferative syndrome (ALPS) ................................................................................................................ 5 APECED / APS1 with CMC - Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) .................. 5 Barth syndrome ...........................................................................................................................................................................
    [Show full text]
  • Interactions Between Activated Platelets and the Complement System
    REVIEW published: 10 July 2019 doi: 10.3389/fimmu.2019.01590 The Human Platelet as an Innate Immune Cell: Interactions Between Activated Platelets and the Complement System Oskar Eriksson 1, Camilla Mohlin 2, Bo Nilsson 1 and Kristina N. Ekdahl 1,2* 1 Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, 2 Linnaeus Center of Biomaterials Chemistry, Linnaeus University, Kalmar, Sweden Platelets play an essential role in maintaining homeostasis in the circulatory system after an injury by forming a platelet thrombus, but they also occupy a central node in the intravascular innate immune system. This concept is supported by their extensive interactions with immune cells and the cascade systems of the blood. In this review we discuss the close relationship between platelets and the complement system and the role of these interactions during thromboinflammation. Platelets are protected Edited by: from complement-mediated damage by soluble and membrane-expressed complement Benoît Ho-Tin-Noé, regulators, but they bind several complement components on their surfaces and Institut National de la Santé et de la Recherche Médicale trigger complement activation in the fluid phase. Furthermore, localized complement (INSERM), France activation may enhance the procoagulant responses of platelets through the generation Reviewed by: of procoagulant microparticles by insertion of sublytic amounts of C5b9 into the platelet Craig Norman Morrell, University of Rochester, United States membrane. We also highlight the role of post-translational protein modifications in Viviana P. Ferreira, regulating the complement system and the critical role of platelets in driving these University of Toledo, United States reactions. In particular, modification of disulfide bonds by thiol isomerases and protein Kerstin Jurk, Johannes Gutenberg University phosphorylation by extracellular kinases have emerged as important mechanisms to Mainz, Germany fine-tune complement activity in the platelet microenvironment.
    [Show full text]
  • Clinical and Laboratory Associations of Mannose-Binding Lectin in 219 Adults with Igg Subclass Deficiency James C
    Barton et al. BMC Immunology (2019) 20:15 https://doi.org/10.1186/s12865-019-0296-x RESEARCHARTICLE Open Access Clinical and laboratory associations of mannose-binding lectin in 219 adults with IgG subclass deficiency James C. Barton1,2,3* , Jackson C. Barton2 and Luigi F. Bertoli2,3,4 Abstract Background: Mannose-binding lectin (MBL) deficiency may increase risk of respiratory tract infection in adults unselected for IgG or IgG subclass levels. In a retrospective study, we sought to determine associations of serum MBL levels with clinical and laboratory characteristics of unrelated non-Hispanic white adults at diagnosis of IgG subclass deficiency (IgGSD). We computed the correlation of first and second MBL levels expressed as natural logarithms (ln) in a patient subgroup. We compared these characteristics of all adults with and without MBL ≤50 ng/mL: age; sex; body mass index; upper/lower respiratory tract infection; diabetes; autoimmune condition(s); atopy; other allergy; corticosteroid therapy; and subnormal serum IgG subclasses, IgA, and IgM. We performed logistic regression on MBL ≤50 ng/mL (dichotomous) using the three independent variables with the lowest values of p in univariate comparisons. Results: There were 219 patients (mean age 51 ± 13 y; 82.5% women). Thirty-six patients (16.4%) had MBL ≤50 ng/ mL. Two MBL measurements were available in 14 patients. The median interval between the first and second measurements was 125 d (range 18–1031). For ln-transformed data, we observed adjusted r2 = 0.9675; Pearson correlation coefficient 0.9849; and p < 0.0001. Characteristics of patients with and without MBL ≤50 ng/mL did not differ significantly in univariate comparisons.
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency Francisco A
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD*; I. Leonard Bernstein, MD†; David A. Khan, MD‡; Zuhair K. Ballas, MD§; Javier Chinen, MD, PhD¶; Michael M. Frank, MDʈ; Lisa J. Kobrynski, MD**; Arnold I. Levinson, MD††; Bruce Mazer, MD‡‡; Robert P. Nelson, Jr, MD§§; Jordan S. Orange, MD, PhD¶¶; John M. Routes, MDʈʈ; William T. Shearer, MD, PhD***; and Ricardo U. Sorensen, MD††† TABLE OF CONTENTS I. Preface....................................................................................................................................................................................S1 II. Executive Summary...............................................................................................................................................................S2 III. Algorithms .............................................................................................................................................................................S7 IV. Summary Statements ...........................................................................................................................................................S14 V. General Considerations........................................................................................................................................................S20 VI. Humoral Immunodeficiencies .............................................................................................................................................S24
    [Show full text]
  • IG Living February-March 2009
    IMMUNE GLOBULIN COMMUNITY www.IGLiving.com February–March 20 0 9 IG MANUFACTURING: Up Close and Personal PATIENT SAFETY UPDATE: What’s Happening With the PDMA? U.S. $3.00 Dosing Alternatives in Subcutaneous Immunoglobulin Therapy — Page 32 Features Our mission is to support the IG community through education, communication and advocacy Patient Safety Update: A community service from FFF Enterprises, Inc. 11 What’s Happening With the PDMA? By Amanda M. Traxler Advisory Board Erika Lawrence, PhD Assistant Professor, Department of Psychology University of Iowa Todd Levine, MD Director, Department of Neurophysiology Good Samaritan Hospital, Phoenix Assistant Professor of Clinical Neurology, University of Arizona Jim Mathews, RPh, MSA Vice President of Strategic Operations NuFACTOR Specialty Pharmacy Fred Modell Co-founder of the IG Manufacturing: Jeffrey Modell Foundation 24 Up Close and Personal Marc Riedl, MD, MS Assistant Professor, Department of Medicine By Kris McFalls Clinical Immunology and Allergy UCLA, David Geffen School of Medicine Publisher Patrick M. Schmidt Editor Amanda M. Traxler Assistant Editor Cheryl Brooks Proofreader Jackie Logue Creative Director Sheryl Perez Artistic Director Allan Bean Graphic Artists Allan Bean Ben Drolet Caroline Carlson Contributing Writers Melvin Berger, MD, PhD Catherine Billey Cheryl L. Haggard About IG Living Mark T. Haggard IG Living is the only magazine dedicated to bringing comprehensive healthcare information, immune globulin information, Kris McFalls community and reimbursement news, and resources for successful living directly to immune globulin consumers and their Jim Trageser healthcare providers. Amanda M. Traxler IG Living, published bimonthly, is a community service provided by FFF Enterprises, 41093 County Center Drive, Temecula, CA 92591, (800) 843-7477 x1143, fax (951) 699-9655.
    [Show full text]
  • Primary Immunodeficiencies
    CHAPTERIII Erkrankungen 22 der Genitalorgane Primary Immunodeficiencies structural genes, and also perhaps on the lack of 2/4 C4 A World in Motion genes [506]. MBL deficiency is due to one of three point mutations in the gene for MBL, each of which reduces Primary immunodeficiencies (PIDs), once considered levels of the lectin by interfering with the protein to be very rare,are now increasingly recognized because oligomerization [351]. In children with this kind of of growing knowledge in the immunological field and deficiency, the level of MBL is 4.9 mg/l compared to the the availability of more sophisticated diagnostic tech- 143 mg/l in controls [487]. Regardless of whether the niques and therapeutic modalities [161]. However in a children are homozygote (HZ) or heterozygote (HET) in database of >120,000 inpatients of a general hospital for relation to a given mutation, the defect appears to be conditions suggestive of ID 59 patients were tested, and more consistent in small babies aged 6–18 months [487], an undiagnosed PID was found in 17 (29%) of the sub- who show an immaturity in providing immune re- jects tested [107]. The publication of the first case of sponse to capsular bacteria and in whom low levels of agammaglobulinemia by Bruton in 1952 [60] demon- opsonin are incapable of compensating for this [506]. strated that the PID diagnosis is first done in the labora- The risk of contracting infections is similar in HZs [175] tory. However, PIDs require specialized immunological and HETs [486], though it persists throughout life in centers for diagnosis and management [33].
    [Show full text]
  • Treatment of Selective Iga Deficiency
    Immune Deficiency Foundation Patient & Family Handbook for Primary Immunodeficiency Diseases Australasian Edition This book contains general medical information which cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this book should not be used as a substitute for professional medical advice. Australasian Edition COPYRIGHT 1987, 1993, 2001, 2007, 2013 IMMUNE DEFICIENCY FOUNDATION Copyright 2013 by Immune Deficiency Foundation, USA. Readers may redistribute this article to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. The Immune Deficiency Foundation Patient & Family Handbook may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from the Immune Deficiency Foundation. If you have any questions about permission, please contact: Immune Deficiency Foundation, 110 West Road, Suite 300, Towson, MD 21204, USA; or by telephone at 800-296-4433. Immune Deficiency Foundation Patient & Family Handbook for Primary Immunodeficency Diseases Australasian Edition The printing of the Australasian Edition was made possible by Immune Deficiencies Foundation Australia (IDFA) PO Box 969 Penrith NSW 2751 www.idfa.org.au [email protected] Immune Deficiency Foundation 110 West Road, Suite 300 Towson, MD 21204 800-296-4433 www.primaryimmune.org [email protected] EDITORS R. Michael Blaese, MD, Executive Editor Francisco A. Bonilla, MD, PhD Immune Deficiency Foundation Boston Children’s Hospital Towson, MD Boston, MA E. Richard Stiehm, MD M. Elizabeth Younger, CPNP, PhD University of California Los Angeles Johns Hopkins Los Angeles, CA Baltimore, MD CONTRIBUTORS Mark Ballow, MD Joseph Bellanti, MD R.
    [Show full text]
  • Chronic Burkholderia Multivorans Bronchial Infection in a Non-Cystic
    168 CASE REPORT Thorax: first published as 10.1136/thx.2003.016493 on 28 January 2005. Downloaded from Chronic Burkholderia multivorans bronchial infection in a non-cystic fibrosis individual with mannose binding lectin deficiency J L Whitehouse, A R Exley, J Foweraker, D Bilton ............................................................................................................................... Thorax 2005;60:168–170. doi: 10.1136/thx.2003.016493 On examination the patient had a small goitre but was The case history is presented of a woman with multiple clinically euthyroid. There was no finger clubbing. Her lungs respiratory infections and mannose binding lectin (MBL) were clear and the heart sounds were normal. Abdominal deficiency but no evidence of bronchiectasis who developed examination was unremarkable. a chronic Burkholderia multivorans infection. Careful micro- biological assessment is needed in patients with recurrent Investigations respiratory infection and the presence of B multivorans Baseline blood tests including full blood count, renal and should trigger further immunological investigation including liver function, complement levels, and serum immunoglobu- assessment of MBL status. lins were normal. Aspergillus precipitins were negative, as was an autoantibody screen. Aspergillus RAST in 2001 was negative. The chest radiograph was normal. High resolution computed tomography (HRCT) of the chest showed bronchial he pathogen Burkholderia multivorans (previously called wall thickening in both lower lobes only. In particular, there Burkholderia cepacia, genomovar II) is well recognised in was no evidence of bronchiectasis. Skin prick testing against cystic fibrosis (CF) and chronic granulomatous disease a wide range of common environmental allergens including T 1 (CGD). A previous report described a mother of two patients Aspergillus fumigatus was negative, and spirometric para- with CF who developed B cepacia infection.
    [Show full text]